Trials / Completed
CompletedNCT03336216
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 205 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cabiralizumab | specified dose on specified days |
| DRUG | Nab-paclitaxel | specified does on specified days |
| DRUG | Onivyde | specified dose on specified days |
| BIOLOGICAL | Nivolumab | specified dose on specified days |
| DRUG | Fluorouracil | specified dose on specified days |
| DRUG | Gemcitabine | specified dose on specified days |
| DRUG | Oxaliplatin | specified dose on specified day |
| DRUG | Leucovorin | Specified dose on specified days |
| DRUG | Irinotecan Hydrochloride | Specified dose on specified days |
Timeline
- Start date
- 2017-12-18
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2017-11-08
- Last updated
- 2024-07-23
- Results posted
- 2024-07-23
Locations
41 sites across 11 countries: United States, Canada, Denmark, Germany, Italy, Japan, South Korea, Spain, Switzerland, Taiwan, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03336216. Inclusion in this directory is not an endorsement.